+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rigel Pharmaceuticals Inc - logo

Rigel Pharmaceuticals is a clinical-stage biotechnology company that focuses on the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of a variety of diseases. It has been in trials for rheumatoid arthritis, autoimmune thrombocytopenia, lymphoma and others. In addition, Rigel also has two oncology product candidates in development. Founded in 1996, Rigel is headquartered in San Francisco, California.

Autoimmune Hemolytic Anemia Therapeutics Market 2024-2028 - Product Thumbnail Image

Autoimmune Hemolytic Anemia Therapeutics Market 2024-2028

  • Report
  • June 2024
  • 145 Pages
  • Global
From
Gout Therapeutics Market Report 2025 - Product Thumbnail Image

Gout Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
From
From
Autoimmune Collaboration and Licensing Deals 2016-2025 - Product Thumbnail Image

Autoimmune Collaboration and Licensing Deals 2016-2025

  • Report
  • April 2025
  • 500 Pages +
  • Global
From
From
Transforming Growth Factor Beta Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Transforming Growth Factor Beta Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 150 Pages
  • Global
From
From
From
From
Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2025 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator